Exercise pulmonary hypertension group | Non-exercise pulmonary hypertension group | p-value | |
Subjects | 116 | 133 | |
Age years | 67±11 | 60±15 | <0.001 |
Male:female | 23:93 | 39:94 | 0.106 |
BMI kg·m−2 | 23.2±3.6 | 24.1±4.3 | 0.076 |
BNP pg·dL−1 | 28 (14–56) | 19 (11–31) | <0.001 |
Hb g·dL−1 | 12.6±1.5 | 12.5±1.7 | 0.505 |
HOT | 40 (34) | 27 (20) | 0.012 |
Prior PEA | 17 (15) | 5 (4) | 0.003 |
BPA sessions | 4.0±1.9 | 3.8±1.6 | 0.541 |
Interval from BPA months | 12 (6–23) | 12 (6–20) | 0.857 |
WHO FC I/II/III | 47/67/2 | 90/43/0 | <0.001 |
6MWD m | 432±102 | 462±105 | 0.024 |
Treatment | |||
PDE5i | 42 (36) | 59 (44) | 0.191 |
SGCS | 8 (7) | 30 (23) | 0.001 |
ERA | 47 (41) | 52 (39) | 0.819 |
PCA | 38 (33) | 37 (28) | 0.397 |
Mean RAP mmHg | 3±2 | 4±2 | 0.017 |
Systolic PAP mmHg | 34±6 | 32±6 | 0.179 |
Diastolic PAP mmHg | 8±4 | 7±4 | 0.220 |
Mean PAP mmHg | 19±3 | 18±3 | 0.011 |
PAWP mmHg | 8±3 | 8±3 | 0.393 |
SaO2 % | 95±3 | 95±3 | 0.317 |
SvO2 % | 71±5 | 73±5 | 0.005 |
CO L·min−1 | 4.6±1.3 | 5.1±1.6 | 0.002 |
PVR WU | 2.5±1.0 | 2.0±0.9 | <0.001 |
Data are presented as n, mean±sd, median (interquartile range) or n (%), unless otherwise stated. BMI: body mass index; BNP: brain natriuretic peptide; Hb: haemoglobin; HOT: home oxygen therapy; PEA: pulmonary endarterectomy; BPA: balloon pulmonary angioplasty; WHO FC: World Health Organization Functional Class; 6MWD: 6-min walk distance; PDE5i: phosphodiesterase type V inhibitor; SGCS: soluble guanylate cyclase stimulator; ERA: endothelin receptor antagonist; PCA: prostacyclin analogue; RAP: right atrial pressure; PAP: pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; SaO2: arterial oxygen saturation; SvO2: mixed venous oxygen saturation; CO: cardiac output; PVR: pulmonary vascular resistance.